Advanced systemic mastocytosis (SM) is a life-threatening neoplasm characterized by uncontrolled growth and accumulation of neoplastic mast cells (MCs) in various organs and a poor survival. So far, no curative treatment concept has been developed for these patients. We identified the epigenetic reader bromodomain-containing protein-4 (BRD4) as novel drug target in aggressive SM (ASM) and MC leukemia (MCL). As assessed by immunohistochemistry and PCR, neoplastic MCs expressed substantial amounts of BRD4 in ASM and MCL. The human MCL lines HMC-1 and ROSA also expressed BRD4, and their proliferation was blocked by a BRD4-specific short hairpin RNA. Correspondingly, the BRD4-targeting drug JQ1 induced dose-dependent growth inhibition and apoptosis in HMC-1 and ROSA cells, regardless of the presence or absence of KIT D816V. In addition, JQ1 suppressed the proliferation of primary neoplastic MCs obtained from patients with ASM or MCL (IC50: 100-500 nM). In drug combination experiments, midostaurin (PKC412) and all-trans retinoic acid were found to cooperate with JQ1 in producing synergistic effects on survival in HMC-1 and ROSA cells. Taken together, we have identified BRD4 as a promising drug target in advanced SM. Whether JQ1 or other BET-bromodomain inhibitors are effective in vivo in patients with advanced SM remains to be elucidated.
INTRODUCTION
Systemic mastocytosis (SM) is a hematopoietic stem cell disorder characterized by pathologic expansion and accumulation of clonal mast cells (MCs) in one or more internal organs. [1] [2] [3] [4] [5] Indolent and advanced types of the disease have been described. [1] [2] [3] [4] [5] The classification of the World Health Organization (WHO) delineates four major categories of SM, namely indolent SM (ISM), SM with an associated clonal hematopoietic non-MC-lineage disease (SM-AHNMD), aggressive SM (ASM) and MC leukemia (MCL). [6] [7] [8] The smoldering subtype of SM, initially considered a subtype of ISM, is now also regarded a separate SM category. 9 In ISM, the prognosis is quite favorable. In fact, despite mediatorrelated symptoms, cosmetic problems and the neoplastic nature of the disease, patients with ISM have a normal or near-normal life expectancy. [5] [6] [7] [8] By contrast, in patients with advanced SM (ASM, SM-AHNMD, MCL) the prognosis is grave. [6] [7] [8] [10] [11] [12] [13] [14] [15] In these patients, cytoreductive therapy is administered to suppress MC expansion in various organ systems. 9, 10, [12] [13] [14] [15] [16] However, unfortunately, clonal MCs in these patients are often resistant against anticancer drugs. Therefore, research efforts focus on new potential drug targets in neoplastic MCs and the development of novel targeted drugs for advanced SM. [16] [17] [18] One potential drug target in ASM and MCL is KIT D816V, an SM-related oncoprotein. 17, 18 This transforming mutant is detectable in a majority of all patients with SM, including ASM and MCL. [19] [20] [21] KIT D816V is expressed in MCs as well as in MC progenitors in these patients, and is considered to contribute substantially to differentiation and survival of neoplastic MCs. [21] [22] [23] However, so far, only a few tyrosine kinase inhibitors were found to counteract the growth and survival of KIT D816V+ neoplastic MCs in patients with advanced SM. 18, [24] [25] [26] [27] One of the most encouraging agents is the multikinase inhibitor PKC412, also known as midostaurin. However, despite impressive efficacy, responses to PKC412 in ASM and MCL are often incomplete or short lived. 27, 28 Therefore, research is seeking additional drug targets expressed by neoplastic MCs.
During the past few years, chromatin-regulatory molecules and related antigens have been examined as potential therapeutic targets in diverse human malignancies. [29] [30] [31] One promising class of targets are the bromodomain-containing proteins. [30] [31] [32] To identify candidate therapeutic targets in the chromatinregulatory network in acute myeloid leukemia (AML), we have recently performed a multiplexed short hairpin RNA (shRNA) screen in a genetically engineered mouse model of AML. 32 In this screen, we identified the 'epigenetic reader' bromodomaincontaining protein-4 (BRD4) as a promising new target in AML. 32 Thus, inhibition of BRD4 by exposure to RNA interference or treatment with JQ1, a drug blocking the specific interactions between BRD4 and acetylated histones, resulted in major antileukemic effects in murine and human AML cells. 32, 33 The aims of the present study were to explore whether neoplastic MCs in MCL and other types of SM express BRD4 and whether BRD4 serves as a druggable target in these incurable malignancies.
PATIENTS AND METHODS Reagents
A description of reagents is provided in the Supplementary Materials. A specification of monoclonal antibodies used is shown in Supplementary  Table S1 .
Patients and isolation of primary neoplastic MCs
Diagnostic bone marrow (BM) samples were obtained from the iliac crest of 62 patients with SM, including 46 with ISM (including one with smoldering subtype of SM), 8 with ASM, 5 with SM-AHNMD and 3 with MCL. Diagnoses were established according to WHO criteria. [6] [7] [8] Patient characteristics are shown in Supplementary Table S2 . BM aspirates were collected in syringes containing preservative-free heparin. All patients gave written informed consent before BM examination. The study was approved by the ethics committee of the Medical University of Vienna. Aspirated BM cells were layered over Ficoll to isolate mononuclear cells. Mononuclear cells were examined for drug responses, expression of BRD4 mRNA and presence of KIT mutations at codon 816 as reported. 21, 34 In one patient with MCL, a KIT D816H mutation was found. In most other patients, neoplastic cells were found to carry KIT D816V (Supplementary Table S2 ). Control samples (normal/reactive BM) were from patients with idiopathic cytopenia (n = 2), lymphomas without BM infiltration (n = 6), autoimmune thyroiditis (n = 1) and chronic myeloid leukemia in major molecular response (n = 1).
Cell lines
The MCL cell line HMC-1 35 were cultured in Iscove's modified Dulbecco's medium with 10% fetal calf serum. 37 ROSA KIT WT cells were maintained in stem cell factor (SCF), and ROSA KIT D816V cells were maintained without SCF. Chinese hamster ovary cells transfected with the murine SCF gene served as a source of SCF. 37 In select experiments, recombinant human SCF (rhSCF) was used. The identity of the HMC-1 and ROSA cell lines was confirmed by mutation analysis and phenotyping. For knockdown experiments, pRRL-SFFV-GFPmir-E was constructed based on pRRL-SGEP 38 by removing the PGK-Puro cassette. Knockdown-validated shRNAs targeting BRD4 or Renilla luciferase (Supplementary Table S3 ) were cloned using XhoI/EcoRI from existing miR-E constructs. Lentivirus was produced by transfection of HEK-293FT cells with shRNA constructs and third-generation lentiviral packaging vectors (pRSV-Rev; Addgene no. 12253; pMD2.G, Addgene no. 12259; Addgene, Cambridge, MA, USA; and pcDNA3.GP4xCTE, kindly provided by Dr A Schambach, Hannover Medical School, Hannover, Germany) as described previously. 38 HMC-1 and ROSA cells were transduced using spin infection (800 g for 90 min at 32°C) in the presence of polybrene (7 μg/ml). GFP+ cells were sorted on a FACSAria (Becton Dickinson Biosciences, San Jose, CA, USA).
Immunocytochemistry and immunohistochemistry
To study the expression of BRD4 in neoplastic MCs, immunocytochemistry and immunohistochemistry were performed according to published protocols. 39, 40 A description of staining techniques used in this study is provided in the Supplementary Material.
Evaluation of MC proliferation
Primary cells (mononuclear cells, 10 × 10 4 cells per well) and cell lines (1-2 × 10 4 cells per well) were cultured in 96-well microtiter plates in RPMI-1640 medium plus 10% fetal calf serum in the absence or presence of JQ1 (5-5000 nM) at 37°C. After 48 h, 3 H-labeled thymidine (0.5 μCi per well) was applied for 16 h. Cells were then harvested in filter membranes and bound radioactivity was measured in a β-counter. In a separate set of experiments, drugs were applied in the absence or presence of either Chinese hamster ovary supernatant containing SCF or rhSCF (200 ng/ml) for 24 h. In another set of experiments, drug combinations were tested, using JQ1 and other drugs (PKC412, cladribine, 5-azacytidine, decitabine, ATRA (all-trans retinoic acid)). After an initial screen, PKC412 and ATRA were identified as potent drug partners. HMC-1 cells were incubated with suboptimal concentrations of JQ1 and ATRA or JQ1 and PKC412 at a fixed ratio of drug concentrations. Synergism was defined as supraadditive effect that was confirmed by calculating combination index (CI) values using Calcusyn software (Calcusyn Biosoft, Ferguson, MO, USA) as reported. 24, 26 Assessment of apoptosis and cell cycle progression in neoplastic MCs A detailed description of apoptosis evaluation techniques and cell cycle progression analysis is provided in the Supplementary Materials.
Evaluation of the expression of activation antigens in drugexposed cells Recent data suggest that JQ1 induces maturation in AML cells. 32, 33 To study the effects of JQ1 on MC differentiation, flow cytometry experiments were performed. HMC-1.1, HMC-1.2, ROSA KIT WT and ROSA KIT D816V cells were incubated in JQ1 (100-5000 nM) at 37°C for 48 h. Then, viable cells were examined for the expression of CD2 (LFA-2), CD9, CD11b (C3biR), CD54 (ICAM-1), CD63 (LAMP-3), CD71 (transferrin receptor), CD95 (FAS), CD117 (KIT), CD203c (E-NPP3) and FcεR1α by flow cytometry on a FACSCalibur. In addition, cells were examined for morphologic signs of maturation by Wright-Giemsa staining.
Histamine release experiments
Histamine release experiments were performed on ROSA KIT WT cells following a standard protocol. 41, 42 A description of the histamine release assay is provided in the the Supplementary Materials.
Quantitative PCR
A detailed description of quantitative PCR experiments is provided in the Supplementary Materials. Primers used in PCR assays are shown in Supplementary Table S4 .
Statistical analysis
Differences in growth and apoptosis in drug-exposed cells were determined by appropriate statistical analysis, including analysis of variance and the Student's t-test. Results were considered to be significantly different when the P-value was o 0.05.
RESULTS

Cytoplasmic BRD4 is expressed abundantly in neoplastic MCs in ASM and MCL
In all 26 SM patients tested, neoplastic MCs were found to exhibit nuclear BRD4 (Figure 1a and Supplementary Table S2 ). In ASM and MCL, neoplastic MCs also expressed substantial amounts of cytoplasmic BRD4 (Figure 1a) . By contrast, in most patients with ISM, MCs expressed only little if any cytoplasmic BRD4 (Figure 1a  and Supplementary Table S2) . We were also able to show that MCs obtained from patients with advanced SM express BRD4 mRNA (Figure 1b) . The MC lines HMC-1.1, HMC-1.2, ROSA KIT WT and ROSA KIT D816V also expressed BRD4 at the mRNA and protein levels ( Figure 1b and Supplementary Figure S1 ). Finally, we confirmed the expression of cytoplasmic BRD4 in primary neoplastic MCs in advanced SM (Supplementary Figure S1) . Preincubation of anti-BRD4 antibody with a BRD4-specific blocking peptide or antibody omission resulted in a negative stain (Supplementary Figure S1) . Neither normal CD34+ progenitor cells nor SCF-dependent cultured (non-neoplastic) MCs expressed substantial amounts of BRD4 (Supplementary Figure S1) . Figure S2) . These data are in line with the notion that KIT D816V confers resistance against imatinib.
17,18
The mitogen-activated protein kinase kinase (MEK) inhibitors RDEA119 and PD0325901, the PI3K/mTOR (phosphoinositide 3-kinase/mammalian target of rapamycin) blocker BEZ235 and ATRA were also found to downregulate BRD4 expression in HMC-1 and ROSA cells. Rapamycin induced a slight decrease in BRD4 mRNA expression in HMC-1.2 and ROSA KIT D816V cells but not in ROSA KIT WT or HMC-1.1 cells. BRD4 mRNA expression remained unchanged after exposure to the other drugs examined, including the signal transducer and activator of transcription 5 blockers piceatannol and pimozide, cladribine (2CdA), and the demethylating agents, 5-azacytidine and decitabine. INCB018424 (ruxolitinib) slightly reduced the expression of BRD4 mRNA in ROSA KIT D816V and HMC-1.2 cells (Supplementary Figure S2) .
The BRD4-targeting drug JQ1 inhibits the proliferation of neoplastic MCs We have recently shown that shRNAs against BRD4 and the BRD4-targeting drug JQ1 inhibit the growth of AML cells. 32, 33 To demonstrate a role for BRD4 as potential target in neoplastic MCs, we applied BRD4-specific shRNAs. BRD4 knockdown was confirmed by quantitative PCR. As visible in Figure 2a and Supplementary Figures S4A and S4B , the shRNA-induced knockdown of BRD4 resulted in a significant growth inhibition of HMC-1 and ROSA cells. The knockdown of BRD4 was also found to decrease MYC mRNA levels in all cell lines (not shown). Figure S6A ). We were also able to confirm the apoptosis-inducing effects of JQ1 on HMC-1 and ROSA cells in a terminal deoxynucleotidyl transferase dUTP nick-end labeling assay (Supplementary Figure S6B) . Finally, we were able to show that shRNAs against BRD4 induce apoptosis in HMC-1 and ROSA cells (not shown).
JQ1 downregulates the expression of CD63, CD71 and FcεRI in neoplastic MCs
Recent data suggest that JQ1 can induce maturation in AML cells. 32, 33 In the present study, we found that JQ1 dosedependently downregulates the expression of CD63 and CD71 in HMC-1 and ROSA cells (Supplementary Figure S7A) and HMC-1.2 cells. In ROSA KIT WT and ROSA KIT D816V cells, JQ1 was also found to suppress the expression of the FcεRI (Supplementary Figure S7B) . Moreover, we found that preincubation of ROSA KIT WT Figure S8) and counteracts IgE-mediated upregulation of CD63 and CD203c (Supplementary Figure S9) . Although JQ1 alone failed to upregulate the expression of differentiation antigens on neoplastic MCs, the drug combination 'JQ1+ATRA' was found to upregulate the expression of CD11b (C3biR) and CD54 (ICAM-1) in HMC-1 and ROSA cells (Supplementary Figure S10A) . By contrast, when used as a single agent, ATRA did not upregulate CD54 or CD11b in HMC-1 or ROSA cells (not shown). ATRA also failed to modulate the expression of CD63 and CD71, and neither JQ1 nor ATRA (as single agents or in Figure S10B) .
Effects of JQ1 on the expression of MYC and BCL-2 family members in MCs Recent data suggest that JQ1 modulates the expression of MYC and various BCL-2 family members in leukemic cells. [43] [44] [45] We found that JQ1 downregulates the expression of BCL-2, MCL-1 and BCL-xL mRNA levels, as well as MYC mRNA expression levels, in HMC-1 and ROSA cells (Supplementary Figure S11) . In addition, we found that JQ1 upregulates BIM mRNA levels in all four cell lines tested (Supplementary Figure S11) . JQ1 synergizes with PKC412 and with ATRA in producing growth inhibition in HMC-1 and ROSA cells As BRD4-targeting drugs may best be applied in combination with other antineoplastic drugs in patients with advanced SM, we screened for suitable drug partners of JQ1. A number of candidates, including cladribine (2CdA), 5-azacytidine and decitabine, did not show synergistic effects with JQ1 (not shown). However, we found that JQ1 strongly synergizes with PKC412 and with ATRA in suppressing the growth of HMC-1 and ROSA cells (Supplementary Figure S12A) . In addition, JQ1 was found to synergize with PKC412 and ATRA in inducing apoptosis in HMC-1 and ROSA cells (Supplementary Figures S12B and S12C ). Synergism was confirmed by calculating CI values ( o1) (not shown).
KIT activation confers resistance against JQ1 in ROSA KIT D816V cells
In a final step, we screened for potential resistance mechanisms that could interfere with JQ1 effects. As KIT has been implicated in MYC activation and upregulates BRD4 expression, we asked whether KIT activation could interfere with JQ1 effects. Indeed, as visible in Figures 4a and b , incubation of ROSA KIT D816V cells with SCF blocked their responsiveness against JQ1. Interestingly, however, SCF did not alter responsiveness of HMC-1.1 and HMC-1.2 cells to JQ1 (Supplementary Figure S13A) . We also asked whether the combination 'JQ1+PKC412' would overcome KITmediated resistance. Indeed, this drug combination was found to produce strong synergistic apoptosis-inducing effects in the presence of SCF in ROSA KIT D816V cells (Supplementary Figure  S13B) .
DISCUSSION
Bromodomain-containing proteins have recently been identified as key regulators of cell cycle progression and growth in various neoplastic cells. [29] [30] [31] [32] [33] One of these regulators appears to be BRD4, an epigenetic reader involved in the regulation of MYC. We have recently shown that BRD4 is a druggable target in AML cells, 32, 33 and similar observations have been made in other tumor models. [43] [44] [45] We here show that BRD4 is abundantly expressed in neoplastic MCs in advanced SM, and that the BRD4-targeting drug JQ1 induces growth inhibition and apoptosis in these cells.
ASMs and MCLs are incurable malignancies characterized by drug resistance and a poor survival. [1] [2] [3] [4] [5] [6] [10] [11] [12] [13] [14] [15] In these patients, neoplastic cells are often resistant against conventional drugs and KIT-targeting tyrosine kinase inhibitors. Therefore, it is important to define new robust targets in these malignancies. We have identified BRD4 as a novel drug target in neoplastic MCs in advanced SM. To the best of our knowledge, this is the first report describing a BET-bromodomain-containing molecule as a target in neoplastic MCs.
We have recently shown that BRD4 is expressed abundantly in the cytoplasm of leukemic blasts in AML. 33 In the present study, we show that BRD4 is expressed abundantly in the cytoplasm and the nuclei of neoplastic MCs in almost all patients with advanced SM, whereas in most patients with ISM, MCs expressed only low levels or no detectable BRD4 in their cytoplasm but still expressed BRD4 in their nuclei. HMC-1 and ROSA cells also expressed cytoplasmic and nuclear BRD4. The abundant expression of cytoplasmic BRD4 in MCs in advanced SM may have several explanations. One hypothesis is that cytoplasmic expression of BRD4 is indicative of a higher proliferative potential of neoplastic cells. Alternatively, KIT-independent lesions acquired during disease progression promote cytoplasmic BRD4 expression. Indeed, apart from KIT D816V, several additional molecular lesions and pro-oncogenic signaling pathways are expressed in neoplastic MCs in advanced SM. 46, 47 The exact role and biochemical function of cytoplasmic BRD4 in neoplastic MCs remain unknown. However, there is evidence that BRD4 exerts kinase activity and interacts with cytoplasmic antigens, such as SPA-1, in malignant cells. [48] [49] [50] Whether BRD4 also fulfills these functions in neoplastic MCs remains unknown.
So far, little is known about the mechanisms contributing to the expression of BRD4 in neoplastic MCs. In an attempt to define signaling pathways potentially involved in the expression of BRD4, we applied various signal-transduction inhibitors. The multitargeted tyrosine kinase inhibitors PKC412 and dasatinib, which are known to block the kinase activity of KIT D816V, were found to downregulate the expression of BRD4 in HMC-1 and ROSA cells. In addition, we found that various MEK inhibitors and the PI3K/mTOR blocker BEZ235 can downregulate the expression of BRD4 in neoplastic MCs. As MEK as well as PI3K are downstream of KIT, these data suggest that KIT D816V contributes to the expression of BRD4 in neoplastic MCs. This conclusion was supported by the observation that SCF promotes the expression of BRD4 in ROSA KIT D816V cells. However, SCF failed to upregulate the expression of BRD4 in HMC-1 cells. These observations suggest that the expression of BRD4 in MCs depends not only on KIT activation but also on other factors. An interesting observation was that BRD4 mRNA expression levels are slightly higher in HMC-1.1 compared with that in HMC-1.2 cells. The reason for this phenomenon remains unknown.
We have recently shown that the BRD4-targeting drug JQ1 exerts strong antineoplastic effects in drug-resistant AML cells. 33, 34 In the present study, we were able to show that JQ1 induces growth inhibition and apoptosis in primary neoplastic cells obtained from patients with advanced SM as well as in HMC-1 and ROSA cells. In each cell line tested, the effects of JQ1 were dose-dependent, with reasonable IC 50 values, and in each case, growth inhibition was associated with induction of apoptosis.
In AML, JQ1 effects were found to be associated with signs of maturation. 32, 33 We were therefore interested to learn whether exposure to JQ1 would lead to maturation in neoplastic MCs. However, we were not able to detect a morphologically visible maturation-inducing effect of JQ1 in HMC-1 or ROSA cells. Moreover, we were unable to demonstrate that JQ1 induces the upregulation of differentiation-associated antigens in MCs. Rather, JQ1 was found to even downregulate the expression of several key surface antigens in HMC-1 and/or ROSA cells, including CD63 and CD71. Furthermore, JQ1 was found to downregulate the expression of FcεRI and to suppress IgE-dependent histamine release in ROSA cells. Collectively, these data suggest that JQ1 blocks proliferation as well as activation of neoplastic MCs, which may be relevant clinically, as patients with advanced SM not only suffer from organ infiltration but also from the consequences of MC activation and mediator release. [2] [3] [4] [5] [6] The intriguing effects of JQ1 on growth and survival of neoplastic MCs prompted us to ask for optimal drug partners and synergistic antineoplastic effects. Of all drug partners tested, PKC412 and ATRA were found to synergize with JQ1 in inhibiting growth and survival in HMC-1 and ROSA cells.
In a final step, we asked whether resistance against JQ1 may occur in neoplastic MCs. In these experiments, we found that SCF introduces resistance against JQ1 in ROSA KIT D816V cells but not in HMC-1 cells. We also asked whether the synergistic activity of the drug combinations JQ1+ATRA and JQ1+PKC412 would overcome SCF-mediated resistance. Indeed, the combination JQ1+PKC412 was found to overcome SCF-mediated resistance in ROSA, whereas the combination JQ1+ATRA was unable to overcome resistance. This is best explained by the fact that SCF-induced resistance is mediated by the activation of KIT, the principle target of PKC412.
In summary, we have shown that BRD4 is a druggable target in neoplastic MCs. Inhibition of BRD4 by JQ1 is a potent approach to eradicate neoplastic MCs, and drug effects can be potentiated by the addition of PKC412 or ATRA. Whether BET-targeting drugs exert beneficial effects in patients with advanced SM remains to be determined.
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